Table of Contents
Clinical Takeaway
Cannabinoid-based treatments, including CBD-rich preparations, have shown promising early results for certain autism-associated symptoms such as behavioral challenges, anxiety, and sleep difficulties. However, the current evidence base remains limited in size and methodological rigor, and no definitive clinical recommendations can yet be made. More large-scale, well-designed randomized controlled trials are needed before cannabinoids can be considered a standard therapeutic option for autism spectrum disorder.
#18 Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.
Citation: Riera Rachel et al.. Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.. Journal of clinical pharmacology. 2025. PMID: 40605143.
Design: 5 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: 0
Abstract: Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism-diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
What This Study Teaches Us
This systematic review of 11 randomized trials found only weak evidence that whole plant cannabis extract might improve overall autism symptoms, with most other outcomes showing uncertain benefit. The review identified five different cannabis formulations tested across studies, but the heterogeneity and very low certainty of evidence make it impossible to draw firm conclusions about efficacy.
Why This Matters Clinically
Families and clinicians managing autism are increasingly asking about cannabis, but this review shows we lack the rigorous data needed to guide that conversation. Without clear evidence of benefit and quality of life data notably absent, recommending cannabis for autism remains speculative rather than evidence-based.
Study Snapshot
| Study Design | Systematic review of randomized controlled trials following Cochrane methodology and PRISMA 2020 reporting standards |
| Population | Individuals with diagnosed autism spectrum disorder. Four RCTs included children and adolescents; not specified in abstract whether adults were included in other trials |
| Intervention | Five different cannabis presentations tested; specific doses, formulations, and treatment durations not detailed in abstract |
| Primary Outcome | Global assessment of autism symptoms and other clinical outcomes; quality of life was not assessed in any included study |
| Key Result | One trial suggested cannabis whole plant extract may improve global symptoms; certainty of evidence ranged from very low to low across all outcomes |
Where This Paper Deserves Skepticism
The abstract reveals critical gaps rather than weaknesses in individual studies. Only 11 RCTs emerged from 1264 references, and only four enrolled children/adolescents specifically, suggesting the autism-cannabis evidence base is extremely thin. The heterogeneity of cannabis presentations and outcome measures prevented pooling of data, so we’re left with single-trial findings rather than synthesized estimates. The complete absence of quality of life assessment is telling, since that’s often the reason families pursue cannabis therapy.
Dr. Caplan’s Take
I see this review as honest about our limitations rather than reassuring. When the best available evidence is very low certainty and we lack standardized outcomes or quality of life data, I can’t counsel patients that cannabis is indicated for autism. That doesn’t mean individual patients won’t respond or that research shouldn’t continue, but it means we’re currently working from anecdote rather than evidence. This is a field where more rigorous, larger RCTs with standardized measures could change the picture, but we’re not there yet.
Clinical Bottom Line
Current evidence does not support routine cannabis use for autism spectrum disorder. Clinicians should be honest with families that the data is too sparse and uncertain to guide treatment recommendations at this time.
| |
Have thoughts on this? Share it: